U.S. FDA approves Merck immune-stimulating drug for melanoma
September 04, 2014 at 14:56 PM EDT
Sept 4 (Reuters) - U.S. regulators on Thursday approved the use of Merck & Co Inc's immuno-oncology drug Keytruda, also known as pembrolizumab, as a treatment for patients with advanced melanoma who are no longer responding to other therapies.